Nkarta price target lowered to $25 from $31 at Mizuho

Mizuho lowered the firm’s price target on Nkarta to $25 from $31 and keeps a Buy rating on the shares following the Q4 report. The biggest news is the de-prioritization of NKX101 in acute myeloid leukemia after another look at the data, the analyst tells investors in a research note. The firm removed NKX101 from its model but says an overhang has been removed, which is a positive for the shares.